Neonatal Onset Multisystem Inflammatory Disease Latest Advances

Fatigue in Inactive Auto-Inflammatory Diseases and Opportunities for Optimizing Clinical Care: A Single-Center Observational Study.

Journal: Journal of clinical medicine

Published: October 24, 2025

What is an undifferentiated systemic autoinflammatory disease in adults? Current state of knowledge in 2025

Journal: La Revue de medecine interne

Published: September 08, 2025

Discovery of novel and potent NLRP3 inflammasome inhibitors with new lipophilic moieties.

Journal: European journal of medicinal chemistry

Published: August 15, 2025

Cytological vitreous findings in a patient with infantile neurological cutaneous and articular (CINCA) syndrome.

Journal: BMJ case reports

Published: August 09, 2025

Redox imbalance and NLRP3 activation: H Syndrome mistaken for CAPS-a case report.

Journal: Rheumatology (Oxford, England)

Published: August 08, 2025

Chronic urticaria and autoinflammatory syndromes.

Journal: Current opinion in allergy and clinical immunology

Published: August 01, 2025

TH5487 specifically targets NLRP3 in FCAS patients resistant to MCC950.

Journal: bioRxiv : the preprint server for biology

Published: July 15, 2025

Safety and effectiveness of canakinumab in Japanese patients with cryopyrin-associated periodic syndrome: final results from a post-marketing surveillance in Japan.

Journal: Modern rheumatology

Published: July 09, 2025

Adult onset cryopyrin-associated periodic syndrome due to germline missense mutation in NLRP3 in a previously healthy middle-aged woman.

Journal: Frontiers in immunology

Published: June 23, 2025

Efficacy of budesonide and vedolizumab for IBD-U associated with Muckle-Wells syndrome.

Journal: Clinical journal of gastroenterology

Published: June 17, 2025

Gastrointestinal Involvement in Muckle-Wells Syndrome: A Systematic Review of Clinical Presentation, Diagnostic Patterns, and Therapeutic Response.

Journal: Cureus

Published: May 21, 2025

PET-MRI biomarkers reveal efficacy of a novel NLRP3 inhibitor in Parkinson's disease models.

Journal: Brain : a journal of neurology

Published: April 14, 2025

Filters

Fatigue in Inactive Auto-Inflammatory Diseases and Opportunities for Optimizing Clinical Care: A Single-Center Observational Study.

Fatigue in Inactive Auto-Inflammatory Diseases and Opportunities for Optimizing Clinical Care: A Single-Center Observational Study.

What is an undifferentiated systemic autoinflammatory disease in adults? Current state of knowledge in 2025

What is an undifferentiated systemic autoinflammatory disease in adults? Current state of knowledge in 2025

Discovery of novel and potent NLRP3 inflammasome inhibitors with new lipophilic moieties.

Discovery of novel and potent NLRP3 inflammasome inhibitors with new lipophilic moieties.

Cytological vitreous findings in a patient with infantile neurological cutaneous and articular (CINCA) syndrome.

Cytological vitreous findings in a patient with infantile neurological cutaneous and articular (CINCA) syndrome.

Redox imbalance and NLRP3 activation: H Syndrome mistaken for CAPS-a case report.

Redox imbalance and NLRP3 activation: H Syndrome mistaken for CAPS-a case report.

Chronic urticaria and autoinflammatory syndromes.

Chronic urticaria and autoinflammatory syndromes.

TH5487 specifically targets NLRP3 in FCAS patients resistant to MCC950.

TH5487 specifically targets NLRP3 in FCAS patients resistant to MCC950.

Safety and effectiveness of canakinumab in Japanese patients with cryopyrin-associated periodic syndrome: final results from a post-marketing surveillance in Japan.

Safety and effectiveness of canakinumab in Japanese patients with cryopyrin-associated periodic syndrome: final results from a post-marketing surveillance in Japan.

Adult onset cryopyrin-associated periodic syndrome due to germline missense mutation in NLRP3 in a previously healthy middle-aged woman.

Adult onset cryopyrin-associated periodic syndrome due to germline missense mutation in NLRP3 in a previously healthy middle-aged woman.

Efficacy of budesonide and vedolizumab for IBD-U associated with Muckle-Wells syndrome.

Efficacy of budesonide and vedolizumab for IBD-U associated with Muckle-Wells syndrome.

Gastrointestinal Involvement in Muckle-Wells Syndrome: A Systematic Review of Clinical Presentation, Diagnostic Patterns, and Therapeutic Response.

Gastrointestinal Involvement in Muckle-Wells Syndrome: A Systematic Review of Clinical Presentation, Diagnostic Patterns, and Therapeutic Response.

PET-MRI biomarkers reveal efficacy of a novel NLRP3 inhibitor in Parkinson's disease models.

PET-MRI biomarkers reveal efficacy of a novel NLRP3 inhibitor in Parkinson's disease models.